Docoh
Loading...

CUE Cue Biopharma

Filed: 14 Jun 21, 4:00pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 9, 2021

 

 

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

 

Delaware

 

001-38327

 

47-3324577

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

21 Erie Street

Cambridge, Massachusetts

 

02139

(Zip Code)

(Address of principal executive offices)

 

 

(617) 949-2680

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share

 

CUE

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 



 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

Cue Biopharma, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2021. The certified results of the matters voted upon at the Annual Meeting, which are more fully described in the Company’s Proxy Statement for the Annual Meeting as filed with the Securities and Exchange Commission on April 26, 2021, are as follows:

The Company’s stockholders elected the following nominees to the Company’s Board of Directors to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:

 

��

 

 

 

 

 

 

 

 

 

 

 

 

 

  

For

 

  

Withheld

 

  

Broker Non-Votes

 

Frederick Driscoll

  

 

9,461,702

 

  

 

3,206,417

 

  

 

9,228,349

 

Aaron Fletcher

  

 

12,555,043

 

  

 

113,076

 

  

 

9,228,349

 

Cameron Gray

  

 

12,594,641

 

  

 

73,478

 

  

 

9,228,349

 

Tamar Howson

  

 

12,636,620

 

  

 

31,499

 

  

 

9,228,349

 

Peter Kiener

  

 

12,552,191

 

  

 

115,928

 

  

 

9,228,349

 

Frank Morich

  

 

9,232,310

 

  

 

3,435,809

 

  

 

9,228,349

 

Daniel R. Passeri

  

 

12,619,868

 

  

 

48,251

 

  

 

9,228,349

 

The Company’s stockholders ratified the appointment of RSM US LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021, with votes cast as follows:

 

 

 

 

 

 

 

 

For

 

Against

 

Abstain

 

21,760,723

 

38,286

 

97,459

 



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Cue Biopharma, Inc.

 

 

 

 

Date: June 14, 2021

 

 

 

By:

 

/s/ Daniel R. Passeri

 

 

 

 

Name: Daniel R. Passeri

 

 

 

 

Title: Chief Executive Officer